A

Artemis Medicare Services Limi

ARTEMISMED
Market snapshot · 2026-08-11 12:59 UTC

313.30

₹-2.65 (-0.84%)

MARKET CAP

STOCK P/E

136.8x

52W HIGH

₹325.90

52W LOW

₹203.35

BOOK VALUE

₹59.05

EPS

₹2.29

ROE

SECTOR

Industrials

DEBT/EQUITY

27.81

VOLUME

1.73L

P/B RATIO

5.31x

PEG RATIO

2.93

Sector

Industrials

Themes

Business Support Services
D
Dividend
₹316.30₹291.12₹265.93₹240.75₹215.56VolumeDAug '25Sep '25Nov '25Jan '26Mar '26Apr '26Jun '26Aug '26

AI Summary

✦ Clartha

Forecast

Analyst targets, estimate history, and probabilistic forward ranges for ARTEMISMED.

5.00 analysts

Price Forecast

Current
₹315.00
High Target
₹370.00
▲ +17.5%
Median Target
₹343.00
▲ +8.9%
Low Target
₹325.00
▲ +3.2%
Now₹315.00High ₹370.00Median ₹343.00Low ₹325.00Aug '25Now12M Target
Price history (1Y)
Analyst target range
5 analysts

Probabilistic Range

Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.

Time horizonRange ()Probability
3M₹256.73 - ₹404.7580%
6M₹239.08 - ₹455.1580%
12M₹219.11 - ₹544.6280%
Realized vol: +35.5% · Drift: +15.5%

Revenue Forecast

₹ Cr
Jun '26Current₹282.0
Sep 2026 ETrend estimate range
High₹337.3Base₹312.3Low₹287.3
Sep '25: ₹270.0 · Dec '25: ₹267.0 · Mar '26: ₹274.0 · Jun '26: ₹282.0 · Sep '26: ₹312.3 · Dec '26: ₹308.8
Sep '25Dec '25Mar '26Jun '26Sep '26 EDec '26 E270.0267.0274.0282.0312.3308.8
PastCurrentTrend estimate: Low / Base / High

EPS Forecast

₹ / share
Jun '26Current₹1.96
Sep 2026 ETrend estimate range
High₹2.68Base₹2.39Low₹2.10
Sep '25: ₹2.16 · Dec '25: ₹1.42 · Mar '26: ₹1.87 · Jun '26: ₹1.96 · Sep '26: ₹2.39 · Dec '26: ₹1.57
Sep '25Dec '25Mar '26Jun '26Sep '26 EDec '26 E2.161.421.871.962.391.57
PastCurrentTrend estimate: Low / Base / High
Market Intelligence

Multi-factor synthesis of 5 key dimensions

Overall Outlook
Neutral
65%
Analyst Consensus
Positive

From 5 analysts

Mean upside+9.7%

Fundamentals

Strong

Fundamentals institutional score is 87 using growth durability 86.7.

Valuation

Fairly valued

Valuation institutional score is 54 using relative multiple z-scores where peer dispersion is available.

Analyst Consensus

Positive

Analyst View institutional score is 80 using mean target upside 9.7%; dispersion penalty 5.2; recommendation breadth from available consensus.

Technical Structure

Weak Structure

Technicals institutional score is 22 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.

Market Sentiment

Positive catalysts emerging

Recent news flow is balanced or not decisive enough to tilt the tape. Based on 2 recent ticker-linked news items.

Signal Summary

Market intelligence remains Neutral. fundamentals and analyst consensus provide support, while valuation and technical structure remain considerations.

Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.

Fundamentals StrongValuation Fairly valuedAnalyst Consensus PositiveTechnical Structure Weak StructureMarket Sentiment Positive catalysts emerging

Key Data Points

Mean Target Price345.6 target
Mean Upside+9.7%
Technical Score22%
Fundamental Score87%
Data CoverageHigh

Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.

Valuation Metrics

Trading 28.6% above historical median. Valuation is declining — currently in the strongly overvalued zone (z-score: +1.56). Confidence: 78%.

Live forward EPS implies next-12-month EPS of ₹12.43. Applying the stock's normalized valuation corridor produces a fair range of ₹993.41 to ₹1,479.42, with base value near ₹1,321.81 (+321.9% vs current price).

Forward Valuation Outlook

Live forward estimate anchored to the company's historical valuation corridor.

Below normalized range

Forward EPS

₹12.43

Forward P/E

25.2x

Base Fair Value

₹1,321.81

Fair Range

₹993.41 - ₹1,479.42

Upside To Base

+321.9%

Estimate Source

Live forward EPS

Growth Estimate

+46.7%

P/E
Strongly Overvalued

5Y Average

74.19

Current

136.81

Overvalued

119.02

Undervalued

79.92

EV/EBITDA
Strongly Overvalued

5Y Average

14.39

Current

26.53

Overvalued

21.67

Undervalued

5.87

P/B
Undervalued

5Y Average

Current

5.31

Overvalued

6.10

Undervalued

4.51

Peers & Comparison

Sector: Industrials · Theme: Business Support Services

Business Support Services Peers4 peers
Avg P/E: 38.4x
CompanyRev. GrowthMarginP/Evs Avg52W Perf.
KFIN TECHNOLOGIES LIMITED
KFINTECHBusiness Support Services
+30.1%24.4%
47.9x
Premium
+25% vs avg
-14.5%
INDEGENE LIMITED
INDGNBusiness Support Services
+39.7%10.5%
34.2x
Fair
-11% vs avg
-1.0%
RITES LIMITED
RITESBusiness Support Services
+8.7%17.0%
26.2x
Undervalued
-32% vs avg
-6.5%
SIS LIMITED
SISBusiness Support Services
+29.7%0.9%
45.3x
Premium
+18% vs avg
+17.4%
WHY THESE PEERS

ARTEMIS MED SERVICE LTD trades at a premium (136.8x vs peer avg 38.4x), implying higher growth or quality expectations from the Business Support Services cohort. Peers include KFIN TECHNOLOGIES LIMITED, INDEGENE LIMITED, RITES LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.

Financials

Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.

Latest revenue

₹282 CrJun 2026

Latest net profit

₹31 CrJun 2026

Latest EPS

₹1.96Jun 2026

Net margin

20.0%Jun 2026

Performance

Bars show revenue and net profit. The line shows net margin.

Rs crore + margin %
Q1 '26Q2 '26Q3 '26Q4 '26Q1 '270.0%5.0%10.0%15.0%20.0%0.00 Cr75 Cr150 Cr225 Cr300 Cr
  • Revenue
  • Net income
  • Net margin %

Earnings

Revenue is shown in crores. EPS is rupees per share.

Rs crore + Rs/share
Q1 '26Q2 '26Q3 '26Q4 '26Q1 '270.00 Cr75 Cr150 Cr225 Cr300 Cr₹0₹1₹1₹2₹2
  • Revenue
  • EPS

Revenue to profit conversion

Bridge from operating numbers to profit for the latest reported period.

Rs crore
RevenueExpensesDepreciationOtheradjustmentsOperatingprofitOther incomeInterestOtheradjustmentsProfitbefore taxTax & otherNet Profit0.00 Cr75 Cr150 Cr225 Cr300 Cr

Latest reported period: Jun 2026

Debt level and coverage

Debt, cash and free cash flow compared on the same crore scale.

Rs crore
Annual view
Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-500 Cr0.00 Cr500 Cr1.00K Cr1.50K Cr
  • Debt
  • Free cash flow
  • Cash & equivalents

Results

MetricJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales +201217210217217235227235250270267274282
Expenses +174184179181181193190199209220223224227
Operating Profit27333236364237364150445055
OPM %14%15%15%17%16%18%16%15%16%19%16%18%20%
Other Income +12224891278485
Interest6788888877766
Depreciation991010101111111111121212
Profit before tax13191619223127293040303942
Tax %26%27%29%28%24%27%23%20%29%25%24%25%26%
Net Profit +10141214172321232130233031
EPS in Rs0.731.010.851.021.241.641.511.691.542.161.421.871.96
Raw PDF
YOY Sales Growth %23.07%18.89%15.91%15.95%7.80%8.19%7.91%8.27%15.17%14.96%17.73%16.61%12.89%
Employee Cost %16.22%15.14%15.87%16.03%15.98%14.79%16.02%16.18%14.94%14.18%15.84%16.06%14.81%
Exceptional items0.000.000.000.000.000.000.000.000.000.00-3.070.000.00
Other income normal1.232.481.711.874.387.508.8012.236.967.787.497.685.40
Exceptional items AT0.000.000.000.000.000.000.000.000.000.00-2.340.000.00
Profit excl Excep9.9413.7711.5113.9216.9222.5620.7823.2021.4229.9624.8529.5531.05
Profit for PE9.9413.7711.5113.9216.9222.5620.7823.2021.4229.9624.8529.5531.05
Profit for EPS9.9413.7711.5113.9216.9222.5620.7823.2021.4229.9622.5129.5531.05
YOY Profit Growth %14.25%40.51%6.67%33.85%70.22%63.83%80.54%66.67%26.60%32.80%19.59%27.37%44.96%

All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).

Shareholding Pattern

HolderJun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters +66.53%66.53%58.38%58.39%58.39%
FIIs +0.24%0.37%12.47%12.19%12.28%
DIIs +4.76%4.27%2.91%2.89%2.40%
Government +7.02%7.02%6.16%6.16%6.16%
Public +21.45%21.81%20.07%20.37%20.76%
Others0.01%0.01%
Jun 2026
Promoters +
FIIs +
DIIs +
Government +
Public +
Others

Events Timeline

Annual Report FY26

FY2026PDFCompany Reports Open

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Aug 10, 2026PDFCompany Reports Open

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Aug 10, 2026PDFCompany Reports Open

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Aug 04, 2026PDFCompany Reports Open

Announcement under Regulation 30 (LODR)-Newspaper Publication

Aug 04, 2026PDFCompany Reports Open